MTOR expression in human testicular seminoma. (9th December 2015)

• Record Type: Journal Article
• Authors: Yaba, A.; Bozkurt, E. R.; Demir, N.
• Is Part Of: Andrologia. Volume 48:Number 6(2016)
• Page Start: 702
• Page End: 707
• Publication Date: 2015-12-09
• Subjects: Autophagy -- mTOR -- testicular seminoma; Andrology -- Periodicals; Infertility, Male -- Periodicals; 616.69
• DOI: 10.1111/and.12504
• Languages: English
• ISSNs: 0303-4569

Abstract

Summary: The mammalian target of rapamycin (TOR) has been implicated in the control of different stressors, growth factors, nutrients and hormones, participating in the control of key cellular functions. Controlling this many pathways poses mTOR signalling as a potential new target in new treatment strategies for multiple cancer types. mTOR components could potentially mislocated in tumour cells, which could lead to activation of signalling pathway that should not be active. Therefore, we aimed to show localisation of mTOR signal proteins in testicular seminoma. Tumoural testicular tissues were obtained from 10 patients with unilateral classic seminoma undergoing to therapeutic orchidectomy and compared with control human testicular tissues. Upon immunohistochemical evaluation, we detected mTOR and p‐mTOR (serine 2448), P70S6K, p‐P70S6K, PKCalpha and p‐PKCalpha, CD36 and MAPLC3 proteins in the cytoplasm of Sertoli cells in the seminiferous tubules. We also showed cytoplasmic perinuclear staining in seminoma cells. This study demonstrated the interaction of mTOR signalling pathway and testicular seminoma by showing intense cytoplasmic mTOR pathway proteins immunoreactivity in the seminoma, for the first time in humans. Therefore, we suggested that mTOR signalling components could create new clinical targets for treatment of testicular seminoma patients and male infertility in the future.